Search

Trichotillomania (TTM) is an intractable and chronic mental disorder that causes significant distress or functional impairments in various life domains. Most individuals with trichotillomania have other comorbid diagnoses. Bipolar disorder (BD) is one of the most common comorbid conditions. Up to date, no FDA-approved drugs for TTM are available, not to mention children and adolescent patients with TTM and BD. Here, we present a case of an 8-year-old child with a long history of episodic TTM and bipolar disorder who was effectively treated with topiramate in a 3-year follow-up. [ABSTRACT FROM AUTHOR]

We prove some new characterizations of strongly continuous lattices using two new intrinsic topologies and a class of convergences. Lastly we show that the category of strongly continuous lattices and Scott continuous mappings is cartesian closed. [ABSTRACT FROM AUTHOR]

To investigate the efficacy and relationship between plasma concentrations at the end of infusion ( C end of infusion) and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). Patients were given gemcitabine by 120 min infusion [at a fixed dose rate (FDR) of 10 mg/m2/min] on days 1 and 8 of a 21-day cycle, immediately followed by carboplatin AUC 5 by 4 h infusion on day 1. C end of infusion of gemcitabine was determined by ion-pair reversed-phase high-performance liquid chromatography (HPLC). By the close-out date, in our study population, the estimated median time to tumor progression (TTP) was 7 months (95% CI 4–10 months), median overall survival (OS) was 12 months (95% CI 11.2–12.8 months). The mean value of C end of infusion of 21 eligible patients was 16.48 ± 8.07 μmol/l (range 27.43–2.87 μmol/l). The main hematological toxicities were transient grade 3–4 thrombocytopenia. The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 eligible patients were 38.3 ± 38.1%, 31.3 ± 73.6%, 31.8 ± 53.5% and 12.0 ± 12.2%, respectively. The analysis of the C end of infusion of gemcitabine and the percentage of reduction in WBC showed a significant correlation ( r 2 = 0.4575; p < 0.05). A significant correlation ( r 2 = 0.5671; p < 0.05) was also observed between the percentage of reduction of PLTC and C end of infusion of gemcitabine infusion. The clinical data in this trial supports the further evaluation the regimen in advanced NSCLC patients, due to its predictable kinetic behavior and less severe toxicity profile than expected. [ABSTRACT FROM AUTHOR]

Objective: To develop a novel semi‐cannulated lateral mass screw (SC‐LMS) for cervical posterior fixations and compare the fixation stability and safety of SC‐LMS with regular solid lateral mass screw (S‐LMS) in bone cement augmentation and pullout strength using fresh cadaveric cervical vertebrae. Methods: The conventional multiaxial screw for cervical lateral mass fixation was modified to a cannulated screw with two lateral holes, used for bone cement injection in situ. Eight fresh human cervical vertebrae (C3, C4, and C5) were collected and used. μCT scan was performed to evaluate the bone quality of the lateral masses, including bone mineral density (BMD), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). SCLMS or S‐LMS were randomly inserted into the paired cervical vertebrae and pulled out as a screw loosening model. These screws were reinserted in with bone cement augmentation, scanned by μCT to obtain the bone cement distribution along the screws, and pulled out to test the screw purchase strength. Results: Fmax values exhibited strong positive correlations with the local BMD (푟 = 0.8640, p < 0.0001) and Tb.Th (푟 = 0.6795, p = 0.0038), whereas a negative correlation with Tb.Sp (푟 = −0.5567, p = 0.0251). A significant difference was observed between the Fmax before and after PMMA injection on the SC‐LMS side (p = 0.019). The SC‐LMS exhibited lower risk of cement leakage than S‐LMS after PMMA injection, and a positive correlation was observed between 퐹max and the distribution volumes on the SC‐LMS side. Conclusion: The novel SC‐LMS provides more robust fixation stability and is safer than the S‐LMS for PMMA augmentation, which may be related to the cement‐screw‐cement‐bone complex formation. [ABSTRACT FROM AUTHOR]

Background/aim: The common disease gastric adenocarcinoma (GAC) has a high morbidity and mortality, so there is an urgent need for research to explore new diagnostic markers and therapeutic targets. This investigation was carried out to investigate the expression of sphingomyelin phosphodiesterase acid-like 3b (SMPDL3B) in GAC and its effects on tumor progression. Materials and methods: Samples were collected from patients who underwent radical gastrectomy from January 2021 to December 2022. Along with the normal gastric epithelial cell lines GES-1 and SGC-7901, the AGS, MGC-803, and MSN-45 human gastric cancer cell lines were used to confirm SMPDL3B expression. RT-qPCR, Western blot, immunohistochemical, cell proliferation, assay of wound healing, transwell migration assay, invasion assay, flow cytometry, and immune evaluation experiments were carried out. Results: SMPDL3B was found to be substantially expressed in GAC, and this condition has a bad prognosis. By establishing SMPDL3B knockdown and overexpression of GAC cell lines, this study confirmed that SMPDL3B promoted tumor cell proliferation, migration, and invasion. Additional bioinformatics research revealed a connection between SMPDL3B and immune cell infiltration in the GAC immunological microenvironment, which enhanced tumor cell proliferation by promoting the infiltration content of M2 macrophages. Conclusion: This study determined the function of SMPDL3B for the clinical diagnosis, prediction, and novel management of GAC. [ABSTRACT FROM AUTHOR]